secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2023-03-10T23:59:59+00:00
Accession:  0001213900-23-019281
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara confirms no material SVB exposure; cash runway into 2025 unchanged
--------------------------------------------------------------------------

- $102.3M cash equivalents invested in short-term treasury/corporate bonds, not SVB.
- Operating account at SVB used only for monthly expenses; minimal balance.
- Company does not expect SVB failure to impact operations or liquidity.
- Reiterates cash runway guidance into 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023019281/0001213900-23-019281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023019281/ea175044-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-019281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer